Introduction {#Sec1}
============

Asthma and its phenotypes are complex traits induced by interactions between the surrounding environment and multiple disease susceptibility genetic factors (Sengler et al. [@CR21]). Allergic asthma has been recognized as an antigen-dependent T-helper type 2 (Th2)-related disease with a cytokine response profile that includes interleukin (IL)-4, IL-5, and IL-13. These cytokines play important roles in the coordination and persistence of the airway inflammatory process in allergic asthma (Cohn et al. [@CR5]).

Recently, the innate, non-antigen-dependent immune system has received as much attention in the pathogenesis of asthma as an antigen-dependent adaptive immune response because adaptive immune responses are dependent on activation of the innate system (Kanzler et al. [@CR11]). Many innate immune receptors, such as the Toll-like receptors (*TLR*), NOD proteins, Dectin, CD14, and collectins, have been discovered (Beutler [@CR2]). *TLR2* is associated with increased allergic inflammation and airway hyper-reactivity in a murine allergic model (Redecke et al. [@CR19]), whereas TLR4 ligands can decrease allergic responses (Velasco et al. [@CR25]). In these processes, dendritic cells (DCs) play a central role in initiating and regulating the adaptive and innate immune responses (Iwasaki and Medzhitov [@CR8]).

Colony-stimulating factor 1 (*CSF1*, also referred to as macrophage *CSF* or *M*-*CSF*) has been found to be an essential factor for the growth, survival, and differentiation of monocyte/macrophages (Stanley et al. [@CR22]). Furthermore, *CSF1* has important roles in DC differentiation and function. *CSF1* upregulates human monocyte expression of the P2X7 extracellular ATP receptor (Zhang et al. [@CR28]), which regulates DCs and macrophage inflammatory function, favoring the generation of cytokines that stimulate T helper 2 responses (la Sala et al. [@CR12]).

*CSF1* acts via specific binding to its high-affinity receptor *CSF1R* (CD115 antigen), encoded by the c-fms proto-oncogene. Upon binding, *CSF1* induces *CSF1R* tyrosine phosphorylation, leading to the activation of *Ras*-*ERK* and *PI3K* and to the formation of DNA-binding complexes containing *STAT*-*1*, *STAT*-*3*, and *STAT*-*5* (Hamilton [@CR6]). The human *CSF1R* gene is located on chromosome 5q33--q35. Whole-genome analyses have shown that chromosome region 5q33--q35 contains a gene cluster of *ADRB2* and *IL17RB* receptors, key molecules contributing to the development of asthma and atopy in several ethnic populations (Holberg et al. [@CR7]; Ober et al. [@CR16]; Xu et al. [@CR26]; Yokouchi et al. [@CR27]). Considering these biological effects of *CSF1R* and its linkage to chromosome 5q33--q35, genetic variants of *CSF1R* may be involved in asthma. However, no report has examined its association with asthma development. In an effort to discover polymorphism(s) in the *CSF1R* gene that may have effects in asthma and related phenotypes, we identified 28 SNPs of the *CSF1R* gene and genotyped them in 498 asthmatic patients and 306 normal controls.

Materials and methods {#Sec2}
=====================

Subjects {#Sec3}
--------

Subjects were recruited from the Genome Research Center for Allergy and Respiratory Diseases at Soonchunhyang University, Bucheon, Seoul, and Chunan Hospital, Korea. All patients were diagnosed by a physician and met the definition of asthma in the Global Initiative for Asthma (GINA) guidelines (Bateman et al. [@CR1]). All patients had a history of dyspnea and wheezing during the previous 12 months, plus one of the following: (1) \>15% increase in FEV~1~ or \>12% increase plus 200 mL following inhalation of a short-acting bronchodilator, (2) \<10 mg/mL PC20 methacholine, and (3) \>20% increase in FEV~1~ following 2 weeks of treatment with systemic or inhaled steroids and long-acting bronchodilators. The normal subjects were recruited from the patients' spouses and members of the general population who had no respiratory symptoms and had an FEV~1~ \> 75% of the predicted value, PC20 methacholine \>10 mg/mL, and normal findings on a plain chest X-ray. Twenty-four common inhalant allergens \[e.g., dust mites (*Dermatophagoides farinae* and *D. pteronyssinus*), aspergillus, cat fur, dog fur, cockroaches, grasses, trees, and ragweed pollens\] were used for a skin prick test. Atopy was defined as having a wheal reaction greater than or equal to histamine or 3 mm in diameter. Total IgE was measured using the Fluoroenzymeimmunoassay (Phadia AB, Uppsala, Sweden). Written informed consent was obtained from all subjects. Study protocols were approved by the Institutional Review Board of Soonchunhyang University Hospital.

Sequence analysis of human *CSF1R* {#Sec4}
----------------------------------

We sequenced *CSF1R* gene, including a promoter region (1.5 kb), to discover single nucleotide polymorphisms (SNPs) in DNA samples from 24 Koreans using the BigDye Terminator (v3.1) Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA) and an ABI PRISM 3700 DNA analyzer (Applied Biosystems). The primer sets used for amplification and sequencing were designed based on sequence information from GenBank (Ref. Genome seq.; NC_000005.8). Information regarding primers is given in Supplementary Table 1 (<http://www.snp-genetics.com/reference/additional_list.asp>).

SNP selection and genotyping {#Sec5}
----------------------------

Nineteen SNPs discovered in the *CSF1R* gene and nine SNPs in the International HapMap database (<http://hapmap.ncbi.nlm.nih.gov/>) were selected for this study (Fig. [1](#Fig1){ref-type="fig"}b). These included three SNPs in the promoter (*−27162C*\>*T*, *−27068C*\>*G*, and *−27022C*\>*T*), 21 SNPs in introns (*−26465G*\>*A*, *−26306G*\>*A*, +*5815C*\>*T*, +*6610A*\>*G*, +*8498T*\>*C*, +*9180C*\>*T*, +*9219A*\>*T*, +*11680G*\>*T*, +*13198G*\>*A*, +*14665G*\>*A*, +*15629G*\>*A*, +*18363C*\>*T*, +*20511C*\>*T*, +*21997C*\>*T*, +*22693T*\>*C*, +*23443G*\>*A*, +*25268C*\>*T*, +*25995C*\>*G*, +*28801C*\>*G*, +*29446G*\>*A*, and +*30473C*\>*A*), three SNPs in exons (+*5648C*\>*T*, +*8313C*\>*T*, and +*15859A*\>*G*), and one SNP in the 3′-UTR (+*33128A*\>*G*). The SNPs were genotyped at a multiplex level using Illumina's Golden Gate genotyping system (Oliphant et al. [@CR17]), and data quality was assessed using duplicate DNA (*n* = 10). The genotype quality score for keeping data was set to 0.25. SNPs that could not satisfy the following criteria were excluded: (1) a minimum call rate of 90%, (2) no duplicate error, and (3) Hardy--Weinberg equilibrium greater than *p* \> 0.001. Twenty-eight SNPs were successfully genotyped. Information about the primers is provided in Supplementary Table 1.Fig. 1Gene map, *p* value, haplotype list, and linkage disequilibrium of SNPs in the *CSF1R* gene. **a** Log *p* values for the association analysis of SNPs with asthma risk. **b** Gene map and locations of the SNPs in the *CSF1R* gene at chromosome 5q33--q35 (60 kb). The first base of the translation start site is denoted as nucleotide +1. The *black* and *white blocks* represent the untranslated regions and coding regions of *CSF1R*, respectively. \*polymorphisms selected for large-scale genotyping, considering allele frequencies, locations, and LD after discovery. \*\*SNPs selected in the HapMap database. *p* values of each SNP were demonstrated in three different models (co-dominant, dominant, and recessive). **c** Haplotypes of *CSF1R*. **d** Linkage disequilibrium coefficient (\|*D*′\| and *r*^*2*^) among *CSF1R* SNPs

Measurement of *CSF1R* protein expression on CD14-positive monocytes and neutrophils of asthmatic patients {#Sec6}
----------------------------------------------------------------------------------------------------------

Neutrophils and mononuclear cells (PBMC) were purified from the heparinized peripheral blood of asthmatic patients using a Percoll gradient (1.115, 1.100, 1.090, and 1.070). Mouse anti-human *M*-*CSF R* mAb (R&D Systems, Minneapolis, USA) was incubated with 5 × 10^5^ PBMC or neutrophils, followed by treatment with 50 μg of PE-conjugated goat anti-mouse IgG (BD Biosciences, San Jose, CA, USA) for *CSF1R* staining. Additionally, PBMC was incubated with FITC-conjugated mouse anti-human CD14 (BD Biosciences). Stained cells were analyzed using a flow cytometer (FACScan, Becton-Dickinson, Mountain View, CA, USA). For isotype-matched controls, PE-conjugated mouse IgG1 (R&D Systems) and FITC-conjugated mouse IgG2a kappa (BD Biosciences) were used, with the same concentration of each antibody tested.

RNA extraction and real-time PCR of *CSF1R* m-RNA {#Sec7}
-------------------------------------------------

Total RNA was isolated from neutrophils using a modified guanidium thiocyanate--phenol--chloroform extraction method (Schreiber et al. [@CR20]). We quantified RNA and reverse transcribed cDNA from 3 μg of total RNA. DNase I (10,000 U/mL; Stratagene, La Jolla, CA, USA)-treated RNA was reverse-transcribed by incubating with 0.5 mM dNTP, 2.5 mM MgCl~2~, 5 mM DTT, 1 μL of random hexamer (50 μg/μL), and SuperScript II RT (200 unit/μL, Life Technologies, Grand Island, NY, USA) at 42°C for 50 min, and heat-inactivated at 70°C for 15 min.

Specific primer pairs for RT-PCR were as follows: β-actin forward: 5′-GGACTTCGAGCAAGAGATGG-3′; β-actin reverse: 5′-AGCACTGTGTTGGCGTACAG-3′ and *CSF1R* forward: 5′-CACCTTCACCCTCTCTCTGC-3′; *CSF1R* reverse: 5′-AGCATCTTCACAGCCACCTT-3′. Amplification was performed for 30 cycles (one cycle: 30 s at 94°C, 30 s at 55°C, and 40 s at 72°C) with initial denaturation at 94°C for 5 min and a final extension at 72°C for 10 min. The size and amount of the PCR products generated were determined by agarose gel electrophoresis in the presence of ethidium bromide and analyzed with the Kodak EDAS 1D analysis package. The cDNA fragment of the *CSF1R* gene contained from exon10 to exon12. cDNA was aliquoted into tubes containing specific primer pairs for human *PGK1* (phosphoglycerate kinase1), human *β*-*actin*, and *CSF1R* genes for amplification (191, 233, and 263 bp fragments, respectively) using RT-PCR. Nucleotide sequences of the primers were as follows: *PGK1* forward: 5′-CCTGGGCGGAGCTAAAGTTG-3′; *PGK1* reverse: 5′-TCTCAGCTTTGGACATTAGGTCT-3′; *β*-*actin* forward: 5′-GGACTTCGAGCAAGAGATGG-3′; *β*-*actin* reverse: 5′-AGCACTGTGTTGGCGTACAG-3′; *CSF1R* forward: 5′-CAGAGCCTGCTGACTGTTGA-3′; *CSF1R* reverse: 5′-TTGCCCTCATAGCTCTCGAT-3. The primers of *PGK1* and *β-actin* were prepared using the Primerbank web server (<http://pga.mgh.harvard.edu/primerbank/>). RT-PCR was performed with the StepOne™ Real-Time PCR System (Applied Biosystems, CA, USA). The reactions were prepared with 20 μL PCR mixture consisting of 10 μL master mix (iQ SYBR Green Supermix; Bio-Rad, Hercules, CA, USA), 1 μg/μL cDNA template, and 1 μL each of the *CSF1R* primer pair. Reactions were denatured at 95°C for 10 min and amplified for 40 cycles at 95°C for 15 s, 57°C for 32 s, and 72°C for 30 s. A melting curve for all products was obtained immediately after amplification by increasing temperature in 0.3°C increments from 60°C for 85 cycles of 15 s each. The threshold cycle (Ct) of *CSF1R* or endogenous reference gene was defined as the fractional cycle number at which the fluorescence of PCR products passed the fixed threshold. Using the 2^−ΔΔCt^ method, the data are presented as the fold change in gene expression, normalized to an endogenous reference gene (*PGK1* and *β-actin*) and relative to a control (+*22693 TT* and +*22693 CC* genotype of *CSF1R*). For the control sample, ΔΔCt equals zero and 2^0^ = 1, so that the fold change in gene expression relative to the control = 1, by definition (Livak and Schmittgen [@CR13]). For the other samples, evaluation of 2^−ΔΔCt^ indicates the fold change in gene expression relative to the control. Fold differences in *CSF1R* mRNA expression in each patient were also calculated by comparing 2^−ΔΔCt^.

Statistical analyses {#Sec8}
--------------------

Linkage disequilibria (LD) between loci were measured as Lewontin's *D*′ (\|*D*′\|) and *r*^*2*^*.* Haplotypes of each individual were inferred using the algorithm (PHASE, version 2.0), developed by Stephens et al. ([@CR23]). The associations of *CSF1R* genotypes and haplotypes with the risk of asthma were analyzed by logistic analysis, controlling for age (continuous value), gender (male = 0, female = 1), smoking status (non-smoker = 0, ex-smoker = 1, smoker = 2) and atopy status (non-atopy = 0, atopy = 1) as co-variables. Statistical analyses were performed using the SAS (v9.1; SAS Institute, Cary, NC, USA) and SPSS software (v11; SPSS, Inc., Chicago, IL, USA). *p* values of \<0.05 were deemed to indicate statistical significance. The effective number of independent marker loci in *CSF1R* was calculated to correct for multiple testing using SNPSpD (<http://genepi.qimr.edu.au/general/daleN/SNPSpD/>) based on the spectral decomposition (SpD) of matrices of pair-wise LD between SNPs (Nyholt [@CR14]). The number of independent marker loci in *CSF1R* was calculated as 4.5008 and 20.0301 in *CSF1R*-ht-block1 and *CSF1R*-ht-block2. The final number of independent marker loci in *CSF1R* was 24.531. In vitro analysis, differences between independent groups and samples were evaluated using a non-parametric Kruskal--Wallis *H* test for continuous data. When significant differences were found, a Mann--Whitney *U* test was performed to detect differences between pairs of samples. Statistical significance was defined as *p* \< 0.05.

Results {#Sec9}
=======

Characteristics of the study subjects {#Sec10}
-------------------------------------

The clinical characteristics of the study subjects are summarized in Table [1](#Tab1){ref-type="table"}. Significant differences were found in mean age and prevalence of smoking between the normal controls and asthmatic patients (*p* = 0.001). FVC, FEV~1~, and PC20 values were significantly lower in the asthmatic subjects than in the normal controls (*p* \< 0.001). IgE level, atopy prevalence, and eosinophil number were significantly higher in the asthmatic patients (*p* \< 0.001).Table 1Clinical profile and laboratory findings of the study subjectsNormal controlsAsthmaticsNumber303498Age (year, range)48 (8--83)43 (11--87)\*Onset of age (year, range)41 (1--75)Percentage of males44.345.1Current/ex-smoker (%)17.5/11.817/20\*FVC (% predicted)93.7 ± 12.482.9 ± 18.1\*\*FEV1 (% predicted)103.09 ± 14.7779.33 ± 22.18\*\*PC20 methacholine (mg/ml)24.29 ± 2.474.02 ± 6.17\*\*Total IgE (IU/ml)115.9 ± 10.8420.0 ± 55.1\*\*Peripheral blood eosinophil (%)2.5 ± 0.15.6 ± 0.25\*\*Atopy (%)33.162.5\*\*Values are mean ± SE\* *p* = 0.001 and \*\* *p* \< 0.001 are obtained using *t* test or χ^2^ test between asthmatics and normal controls

Association of SNPs in *CSF1R* with asthma risk {#Sec11}
-----------------------------------------------

Pair-wise comparisons of the SNPs revealed two sets of absolute LDs (\|*D*′\| = 1 and *r*^*2*^ = 1: *−27068C*\>*G*, *−27022C*\>*T*; +*13198G*\>*A*, +*14665G*\>*A*); several complete LDs (\|*D*′\| = 1 and *r*^*2*^ ≠ 1) were also found (Fig. [1](#Fig1){ref-type="fig"}d). Haplotypes of *CSF1R* were constructed using the PHASE software, and eight major haplotypes with over 5% of MAF were used for further statistical analyses (Fig. [1](#Fig1){ref-type="fig"}c). The genotype distributions of the 28 SNPs were in Hardy--Weinberg equilibrium for all subjects (*p* \> 0.05, Supplementary Table 2). The frequency of each of the 28 polymorphisms and eight haplotypes was compared between the asthmatic participants and normal controls using logistic regression. The allele frequencies in the asthmatic and normal control subjects are shown in Supplemental Table 3, and the *p* values of each SNP are shown in Fig. [1](#Fig1){ref-type="fig"}a. Among the 28 polymorphisms tested, two intronic polymorphisms (+*20511C*\>*T* and +*22693T*\>*C*) were associated with asthma risk (Fig. [1](#Fig1){ref-type="fig"}a; Table [2](#Tab2){ref-type="table"}; *p* = 0.001 in co-dominant and dominant models and *p* = 0.0006 in a recessive model). After correcting for multiple comparisons, the difference remained significant in the two *CSF1R* SNPs (*p* = 0.02 and 0.01, respectively). Frequencies of the T alleles at *CSF1R* +*20511C*\>*T* in the asthmatic group were higher than in the normal control group (49.5 vs. 36.7%, OR = 1.55, *p* = 0.001). In the analysis of the recessive model, the frequency of the C allele at *CSF1R* +*22693T*\>*C* in the asthmatic group was higher than in the normal control group (25.8 vs. 16.4%, OR = 1.99, *p* = 0.0006). The data suggest that the T alleles at *CSF1R* +*20511C*\>*T* and the C allele at *CSF1R* +*22693T*\>*C* have a genetic susceptibility effect on the development of asthma.Table 2Genotype distribution of *CSF1R* polymorphisms in asthmatics (BA) and normal subjects (NC) of the study subjectsLociPositionrsSNPSubject*N* (%)Co-dominantDominantRecessiveC/CC/RR/ROR(95% CI)*pp*^corr^OR(95% CI)*pp*^corr^OR(95% CI)*pp*^corr^+*20511C*\>*T*Intron11rs216144NC166 (63.4)84 (32.1)12 (4.6)1.55 (1.19--2.00)**0**.**0010**.**02**1.67 (1.22--2.28)**0**.**0010**.**03**1.85 (0.94--3.65)0.071BA236 (50.5)195 (41.8)36 (7.7)+*22693T*\>*C*Intron11rs216140NC74 (28.2)145 (55.3)43 (16.4)1.22 (0.98--1.51)0.0810.94 (0.67--1.32)0.7111.99 (1.34--2.95)**0**.**00060**.**01**BA136 (29)212 (45.2)121 (25.8)\* Controlled for age (continuous value), sex (male = 0, female = 1), atopy status (non-atopy = 0, atopy = 1), and smoking status (non-smoker = 0, ex-smoker = 1, smoker = 2) as co-variables. The effective number of independent marker loci in *CSF1R* was calculated to correct for multiple testing, using the software SNPSpD (<http://genepi.qimr.edu.au/general/daleN/SNPSpD>) (Nyholt [@CR14]). The number of independent marker loci in *CSF1R* was calculated as 4.5008 and 20.0301 in ht-block1 and ht-block2

Flow cytometric analysis for *CSF1R* protein expression on peripheral blood CD14-positive monocytes and neutrophils from asthmatic subjects {#Sec12}
-------------------------------------------------------------------------------------------------------------------------------------------

The *CSF1R* expression was measured on peripheral blood neutrophils and CD14-positive monocytes obtained from asthmatic patients by flow cytometry (Fig. [2](#Fig2){ref-type="fig"}). The CD14^+^ monocytes from asthmatic patients with the C alleles at +*22693T*\>*C* showed significantly higher *CSF1R* expression than those with the TT alleles at +*22693T*\>*C* (46.33 ± 4.62 vs. 83.52 ± 12.64, *p* = 0.045; Fig. [2](#Fig2){ref-type="fig"}e). The expression showed a similar trend in neutrophils. The level of *CSF1R* expression was significantly increased on neutrophils having the +*22693* CC alleles versus those having +*22693 T* alleles (2.42 ± 0.3 vs. 5.62 ± 1.75, *p* = 0.044; Fig. [2](#Fig2){ref-type="fig"}f). In contrast, *CSF1R* expression was not different according to the genotypes of *CSF1R* +*20511C*\>*T* (data not shown).Fig. 2*CSF1R* protein expression on CD14^+^ monocytes and neutrophils in the peripheral blood of asthmatic subjects. **a** Gating for CD14^+^ among monocytes using an FITC-conjugated CD14 Ab. **b** Gating for neutrophils using side scatter and forward scatter. **c**, **e** Levels of *CSF1R* expression were compared between monocytes from asthmatic patients with the T or C alleles on *CSF1R* +*22693T*\>*C*. **d**, **f** Levels of *CSF1R* expression were compared between neutrophils from asthmatic patients having the C allele at *CSF1R* +*22693T*\>*C* and having the T allele at *CSF1R* +*22693T*\>*C*

Comparison of *CSF1R* mRNA levels from its SNP subtypes {#Sec13}
-------------------------------------------------------

To investigate the genetic effect of the +*22693 T*\>*C* polymorphism on mRNA expression of the *CSF1R* gene in neutrophils, *CSF1R* mRNA levels were measured. Because *CSF1R* +*22693 T*\>*C* is located in intron 11, we amplified mRNA containing the *CSF1R* gene using primers to detect alternative splicing, as described in "[Materials and methods](#Sec2){ref-type="sec"}" and Fig. [3](#Fig3){ref-type="fig"}a. To identify the RT-PCR products, sequences were examined using the BLAST search program after direct sequencing. The amplified RT-PCR fragment from exon 8 to exon 13 was 758 bp in length (Fig. [3](#Fig3){ref-type="fig"}b) and that of the RT-PCR product from exon 10 to exon 12 was 263 bp. Both of them shared 100% sequence identity with the human *CSF1R* gene. In the RT-PCR products, no alternative splicing was found in the common or rare homozygotes of +*22693 T*\>*C* (Fig. [3](#Fig3){ref-type="fig"}b). Quantitation of mRNA expression in neutrophils from 12 asthmatics was performed by determining the concentration of the *CSF1R* RT-PCR products, corrected by that of *β*-*actin* and *PGK1* (Fig*.* [3](#Fig3){ref-type="fig"}c). The expression level of total *CSF1R* mRNA in neutrophils was higher in patients having +*22693 T* alleles versus those having +*22693 C* alleles (Fig. [3](#Fig3){ref-type="fig"}d).Fig. 3Comparison of *CSF1R* mRNA levels from its SNP subtypes. **a** Diagram of PCR primers. The RT-PCR product size from exon 8 to exon 13 is 758 bp. The RT-PCR product size from exon 10 to exon 12 is 263 bp. **b** Neutrophils containing T allele or C allele were harvested, and *CSF1R* mRNA was measured using RT-PCR. **c** Melt curve using RT-PCR is shown. **d***CSF1R* mRNA was measured using RT-PCR. Data are expressed as the ratio of *CSF1R* mRNA over *β-actin* and *PGK1* mRNA. The experiments were performed in duplicate

Discussion {#Sec14}
==========

In this study, we identified 28 genetic variants in the exons, introns, and flanking region of the *CSF1R* gene. Among them, we discovered that two polymorphisms in introns were associated with a risk of asthma development by logistic analysis. The rare allele frequencies of *CSF1R* +*20511C*\>*T* and *CSF1R* +*22693T*\>*C* were significantly higher in asthmatic patients versus normal controls, and this remained significant after correcting for multiple comparisons. This indicates that the rare alleles, *CSF1R* +*20511C*\>*T* and *CSF1R* +*22693T*\>*C*, in the intron may have some genetic susceptibility effect on the risk of asthma.

Genetic variants exert their effects via alteration of the gene product, the protein. The effects of *CSF1* are mediated by the *CSF1* receptor tyrosine kinase (*CSF1R*) through autophosphorylation of *CSF1R* and the subsequent phosphorylation of downstream molecules. Triggering this phosphorylation cascade increases gene transcription and protein translation and induces cytoskeletal remodeling by several signaling pathways, leading to the survival, proliferation, and differentiation of target cells (Pixley and Stanley [@CR18]). Functional derangement of phosphorylation of *CSF1R* has been documented in pulmonary alveolar proteinosis (PAP). PAP is an autoimmune disorder in which autoantibodies interfere with signaling through the granulocyte--macrophage colony-stimulating factor receptor, leading to macrophage and neutrophil dysfunction (Juvet et al. [@CR10]). Additionally, *CSF1* is able to prime some innate immune responses by modulation of Toll-like receptors. Stimulation of monocytes and macrophages with *CSF1* downregulates the expression of *TLR1*, *TLR5*, *TLR2*, *TLR6*, and *TLR9* (O'Mahony et al. [@CR15]; Sweet et al. [@CR24]) and increases expression of CD14 (Ji et al. [@CR9]). Thus, *CSF1* enhances cytokine production in response to LPS, but suppresses the CpG DNA response (Sweet et al. [@CR24]). These data suggest that *CSF1R* expression may be associated with various inflammatory responses, including the innate immune response, in asthma pathogenesis. However, no association between genetic variants in the *CSF1R* gene or protein has been documented in asthma.

The intronic SNPs of *CSF1R* gene in the present study may lead to differential production in the quantity of *CSF1R* protein or to structural variants. Thus, functional validation is necessary to confirm the genetic effect. To validate the genetic effect of *CSF1R* +*20511C*\>*T* and *CSF1R* +*22693T*\>*C*, the protein level on neutrophils and monocytes was analyzed by flow cytometry because these cells are known to express the receptor on their surface (Buckle et al. [@CR3]). To separate monocytes clearly by flow cytometry, CD14^+^ cells were gated to eliminate other cells. Asthmatic patients having the rare alleles had significantly increased *CSF1R* expression on neutrophils and CD14^+^ monocytes compared with those with the common +*22693T*\>*C* T alleles. These data indicate that the rare allele genotype increases protein expression of *CSF1R* gene, leading to asthma development via differential regulation of neutrophils, monocytes, and other immune cells, including dendritic cells, although we did not measure *CSF1R* protein expression on dendritic cells. Interestingly, *CSF1R* expression was independent from the *CSF1R* +*20511C*\>*T* genotype.

It is well known that intronic SNPs can affect transcript processing through alternative splicing or producing RNA secondary structure (Chen and Stephan [@CR4]). Because the *CSF1R* +*22693T*\>*C* is located in the intron, we next checked the presence of alternatively spliced forms of *CSF1R* by RT-PCR.

No alternative splicing was found in the subjects having rare or common homozygotes. Thus, one of the explanations for the differential protein expression of the *CSF1R* gene may be different mRNA production, due to a change in RNA secondary structure according to genotype (Zuker [@CR29]). The secondary structure containing the C allele of +*22693T*\>*C* has a Δ*G* of *−*127.25 kcal/mol, and the T allele has a Δ*G* of *−*131.45 kcal/mol (Supplemental Fig. 1). These data suggest that this SNP may affect the secondary structure of the *CSF1R* gene. To validate the functional effect of the +*22693 T*\>C on RNA processing, we measured mRNA levels using RT-PCR. We found that mRNA expression in neutrophils having the C alleles at +*22693* C was significantly higher than in those having the T alleles at +*22693*. This indicates that the differential RNA production may be derived from a genetic effect of the SNP.

In summary, we genotyped human *CSF1R* gene polymorphisms and found that the rare allele *CSF1R* +*22693T*\>C was associated with the risk of asthma via increasing *CSF1R* mRNA and protein expression on neutrophils and monocytes. This information on the genetic polymorphism of the *CSF1R* gene may be useful for improving asthma treatment and developing new strategies for controlling bronchial asthma.
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